Recent Advances in the Development of Peptide Vaccines and Their Delivery Systems against Group A Streptococcus

被引：56

作者：

Azuar, Armira ^{[1
]}

Jin, Wanli ^{[1
]}

Mukaida, Saori ^{[1
]}

Hussein, Waleed M. ^{[1
,2
]}

Toth, Istvan ^{[1
,3
,4
]}

Skwarczynski, Mariusz ^{[1
]}

机构：

[1] Univ Queensland, Sch Chem & Mol Biosci, St Lucia, Qld 4072, Australia

[2] Helwan Univ, Fac Pharm, Pharmaceut Organ Chem Dept, Cairo 11795, Egypt

[3] Univ Queensland, Sch Pharm, St Lucia, Qld 4072, Australia

[4] Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia

来源：

VACCINES | 2019年 / 7卷 / 03期

基金：

英国医学研究理事会;

关键词：

peptide-based subunit vaccine; group A Streptococcus antigens; adjuvant; delivery system; M protein; FIBRONECTIN-BINDING PROTEIN; PROTECTIVE IMMUNE-RESPONSES; RHEUMATIC HEART-DISEASE; CROSS-REACTIVE EPITOPES; B-CELL EPITOPES; T-CELL; INTRANASAL VACCINATION; C5A PEPTIDASE; CONSERVED REGION; IMMUNOLOGICAL EVALUATION;

D O I：

10.3390/vaccines7030058

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Group A Streptococcus (GAS) infection can cause a variety of diseases in humans, ranging from common sore throats and skin infections, to more invasive diseases and life-threatening post-infectious diseases, such as rheumatic fever and rheumatic heart disease. Although research has been ongoing since 1923, vaccines against GAS are still not available to the public. Traditional approaches taken to develop vaccines for GAS failed due to poor efficacy and safety. Fortunately, headway has been made and modern subunit vaccines that administer minimal bacterial components provide an opportunity to finally overcome previous hurdles in GAS vaccine development. This review details the major antigens and strategies used for GAS vaccine development. The combination of antigen selection, peptide epitope modification and delivery systems have resulted in the discovery of promising peptide vaccines against GAS; these are currently in preclinical and clinical studies.

引用

页数：26

共 193 条

[1] Structure-activity relationship of a series of synthetic lipopeptide self-adjuvanting group A streptococcal vaccine candidates [J].

Abdel-Aal, Abu-Baker M. ;

Batzloff, Michael R. ;

Fujita, Yoshio ;

Barozzi, Nadia ;

Faria, Andres ;

Simerska, Pavia ;

Moyle, Peter M. ;

Good, Michael F. ;

Toth, Istvan .

JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (01) :167-172

[2]

Allison A C, 1976, Recent Results Cancer Res, P58

[3] LIPOSOMES AS IMMUNOLOGICAL ADJUVANTS [J].

ALLISON, AC ;

GREGORIADIS, G .

NATURE, 1974, 252 (5480) :252-252

[4] Biodegradation and biocompatibility of PLA and PLGA microspheres [J].

Anderson, JM ;

Shive, MS .

ADVANCED DRUG DELIVERY REVIEWS, 1997, 28 (01) :5-24

[5]

[Anonymous], 1946, U S Nav Med Bull, V46, P709

[6]

[Anonymous], 2013, CLIN DEV IMMUNOL

[7]

[Anonymous], 2005, Control of Human African Trypanosomiasis: A Strategy for the African Region, P1

[8] Site-specific effect of polar functional group-modification in lipids of TLR2 ligands for modulating the ligand immunostimulatory activity [J].

Arai, Yohei ;

Inuki, Shinsuke ;

Fujimoto, Yukari .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (09) :1638-1641

[9] Recent progress in adjuvant discovery for peptide-based subunit vaccines [J].

Azmi, Fazren ;

Fuaad, Abdullah Al Hadi Ahmad ;

Skwarczynski, Mariusz ;

Toth, Istvan .

HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (03) :778-796

[10] Modular Peptide Amphiphile Micelles Improving an Antibody-Mediated Immune Response to Group A Streptococcus [J].

Barrett, John C. ;

Ulery, Bret D. ;

Trent, Amanda ;

Liang, Simon ;

David, Natalie A. ;

Tirrell, Matthew V. .

ACS BIOMATERIALS SCIENCE & ENGINEERING, 2017, 3 (02) :144-152

← 1 2 3 4 5 6 7 8 9 10 →